胆汁淤积性肝病的规范化诊断

doi:10.3969/j.issn.1672-5069.2019.05.037

Abstract

Hong Jia, Wu Xiaoning, You Hong. Standardized diagnosis of cholestatic liver diseases[J]. Journal of Practical Hepatology, 2019, 22(5): 758-760.

[1] Trivedi PJ,Corpechot C,Pares A,et al.Risk stratification in autoimmune cholestatic liver diseases:Opportunities for clinicians and trialists. Hepatology,2016,63(2):644-659.
[2] EASL Clinical Practice Guidelines:management of cholestatic liver diseases. J Hepatol,2009,51(2):237-267.
[3] 中华医学会肝病学分会,中华医学会消化病学分会,中华医学会感染病学分会. 胆汁淤积性肝病诊断和治疗共识(2015年). 实用肝脏病杂志,2016,19(6):771-781.
[4] 中华医学会肝病学分会药物性肝病学组. 药物性肝损伤诊治指南. 中华肝脏病杂志,2015,23(11):810-820.
[5] Fontana RJ,Hayashi PH,Barnhart H,et al.Persistent liver biochemistry abnormalities are more common in older patients and those with cholestatic drug induced liver injury. Am J Gastroenterol,2015,110(10):1450-1459.
[6] 中华医学会妇产科学分会产科学组. 妊娠期肝内胆汁淤积症诊疗指南(2015). 临床肝胆病杂志,2015,31(10):1575-1578.
[7] 中华医学会传染病与寄生虫病学分会,肝病学分会. 病毒性肝炎防治方案. 中华传染病杂志,2001,19(1):56-62.
[8] Karlsen TH,Folseraas T,Thorburn D,et al.Primary sclerosing cholangitis-a comprehensive review. J Hepatol,2017,67(6): 1298-1323.
[9] Yang T,Khan GJ,Wu Z,et al.Bile acid homeostasis paradigm and its connotation with cholestatic liver diseases. Drug Discov Today,2019,24(1):112-128.
[10] Ovadia C,Seed PT,Sklavounos A,et al.Association of adverse perinatal outcomes of intrahepatic cholestasis of pregnancy with biochemical markers:results of aggregate and individual patient data meta-analyses. Lancet,2019,393(10174):899-909.
[11] Pollock G,Minuk GY.Diagnostic considerations for cholestatic liver disease. J Gastroenterol Hepatol,2017,32(7):1303-1309.
[12] EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. J Hepatol,2017,67(1):145-172.
[13] Marzorati S, Invernizzi P,Lleo A.Making sense of autoantibodies in cholestatic liver diseases. Clin Liver Dis,2016,20(1):33-46.
[14] Okazaki K,Uchida K,Koyabu M,et al.IgG4 cholangiopathy: current concept,diagnosis,and pathogenesis. J Hepatol,2014,61(3):690-695.
[15] Meeralam Y,Al-Shammari K,Yaghoobi M.Diagnostic accuracy of EUS compared with MRCP in detecting choledocholithiasis:a meta-analysis of diagnostic test accuracy in head-to-head studies. Gastrointest Endosc,2017,86(6):986-993.
[16] Corpechot C.Utility of noninvasive markers of fibrosis in cholestatic liver diseases. Clin Liver Dis,2016,20(1):143-158.

Standardized diagnosis of cholestatic liver diseases

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	National Workshop on Fatty Liver, Alcoholic Liver Disease, Chinese Society of Hepatology; National Workshop on Liver, Metabolism, Chinese Society of Endocrinology, Chinese Medical Association. Committee of Hepatology, Chinese Research Hospital Association; Fatty Liver Expert Committee, Chinese Medical Doctor Association [J]. Journal of Practical Hepatology, 2019, 22(6): 787-792.
[2]	. Consensus on the diagnosis and therapy of hepatic fibrosis [J]. Journal of Practical Hepatology, 2019, 22(6): 793-803.
[3]	Cao Ce, Yu Yixing, Wang Beibei, et al.. Clinical diagnostic efficacy of enhanced magnetic resonance imaging combined with serum AFP and PIVKA-Ⅱ in the diagnosis of patients with hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2019, 22(6): 896-899.
[4]	Zeng Yanni, Zhang Can, Bi Junying, et al.. Value of long-time delayed enhancement scan of MRI in the diagnosis of solitary necrotic nodule of liver [J]. Journal of Practical Hepatology, 2019, 22(6): 900-903.
[5]	Xing Hao, Han Jun, Yang Tian.. Diagnostic value of serum protein induced by vitamin K absence or antagonist II for hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2019, 22(6): 934-937.
[6]	Liang Jubo, Miao Qi, Ma Xiong.. Diagnosis and treatment of cholangiocytic cholestasis [J]. Journal of Practical Hepatology, 2019, 22(6): 941-943.
[7]	Gao Wei, Hou Yong. Diagnostic efficacy of hepatic fibrosis by liver stiffness measurement in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 652-655.
[8]	Huang Hanjun, Lu Fengrong, Zhang Can. Clinical value of MRI scanning based on exchange hemodynamics model in evaluating liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(5): 696-699.
[9]	Lu Lungen. Cholestatic liver diseases：What we know and how to deal with [J]. Journal of Practical Hepatology, 2019, 22(5): 754-757.
[10]	Cheng Hua, Ju Hui, Song Deshun et al. Value of serum angiopoietin-like protein 2 and Golgi protein 73 levels in the diagnosis of hepatic fibrosis in patient with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 494-497.
[11]	Yu Yingfang, Wen Shengbao. Assessment of liver fibrosis with diffusion-weighted magnetic resonance imaging using single, double and stretch index model in patients with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 502-505.
[12]	Zhang Yafei, Ye Jun, Xie Qinxiu, et al. Difference in predicting efficacy of significant liver fibrosis by noninvasive liver fibrosis index in different hospitals [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 510-513.
[13]	Xie Xiao, Liu Ting, Dong Zhixia, et al. Value of controlled attenuation parameter in diagnosis of individuals with liver steatosis by using Fibrotouch [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 526-529.
[14]	Zhang Junfei, Xu Heming, Song Haiyan, et al. Autoimmune hepatitis-primary biliary cholangitis overlap syndrome:poor diagnostic sensitivity of Paris' criteria in Chinese patients [J]. Journal of Practical Hepatology, 2019, 22(4): 537-540.
[15]	Yang Fucun, Shang Huaixue, Gai Yonghao. Enhanced magnetic resonance imaging by gadolinium disodium sebacate in diagnosis of patients with focal liver lesions [J]. Journal of Practical Hepatology, 2019, 22(4): 577-580.